^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter study for pyrotinib maleate in the treatment of advanced non-small cell lung adenocarcinoma with HER2 mutation
Excerpt:
...Confirmed HER2 mutation by Central Laboratoryincluded PCRFISH, NGS; 5. ...
Trial ID:
Source:
Title:
A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Excerpt:
...Confirmed HER2 mutation by Central Laboratory。 7....
Trial ID:
More C2 evidence
Source:
Title:
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Excerpt:
...- HER2 insertion mutation-positive...
Trial ID:
Source:
Title:
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Excerpt:
...- Before enrollment, a documented confirmed presence of activating mutations in exon 20 of the HER2 gene must be provided....
Trial ID:
Source:
Title:
A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2
Excerpt:
...HER2 mutation and amplification confirmed by gene testing of tumor tissue or blood, pleural effusion, cerebrospinal fluid and other specimens;...
Trial ID:
Source:
Title:
An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
Excerpt:
...HER2 mutated non-small cell lung cancer , gastric and gastroesophageal junction adenocarcinoma or Adenocarcinoma of the colon has been confirmed by Pathology....
Trial ID:
Source:
Title:
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Excerpt:
...- have confirmed HER2 gene amplified tumor fluorescence in-situ hybridization (FISH, HER2/cep17 ratio > 2) or HER2 overexpression (IHC 3+) or documented HER2 gene mutation....
Trial ID:
Source:
Title:
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Excerpt:
...Histologically or cytologic confirmed EGFR or HER2 Exon 20 Insertion Mutation positive advanced Non-small cell lung cancer who failed prior therapies....
Trial ID:
Source:
Title:
A Clinical Study of the Effcacy and Safety of Pyrotinib Combined with Chemotherapy in the First-Line Treatment of Patients with HER2-Mutant Advanced Non-Small Cell Lung Cancer
Excerpt:
...Definition of HER2-mutant NSCLC: insertion mutation and point mutation of HER2 gene were confirmed by gene detection of tumor tissue or blood, pleural effusion, cerebrospinal fluid and other samples; 6. ...
Trial ID:
Less C2 evidence
Source:
Title:
1511P - A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer
Published date:
09/14/2020
Excerpt:
Total 25 pts with HER-2 positive/mutations were enrolled….21 (84.0%) pts received 400 mg pyrotinib once daily as initial dose, 2 (8%) pts received 320 mg, 2 (8%) pts received 160 mg...Total 23 pts were eligible for efficacy evaluation, 12 pts achieved PR (4 pts with lung cancer, 4 pts with gastric cancer, 2 pts with colorectal cancer, 2 pts with thymic cancer), 9 pts were SD and 2 pts were PD...The ORR was 52.2% and the DCR was 91.3%...The mPFS was 3.5 months (95%CI: 2.2-5.0 months), mOS was 9.6 months (95%CI: 4.4 months-NR)...The retrospective study showed that pyrotinib showed good efficacy and safety in patients with HER-2 positive/mutation solid tumors...
